PharmaSGP Holding SE's latest marketcap:
As of 06/08/2025, PharmaSGP Holding SE's market capitalization has reached $364.65 M. According to our data, PharmaSGP Holding SE is the 16001th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 364.65 M |
| Revenue (ttm) | 139.12 M |
| Net Income (ttm) | 22.45 M |
| Shares Out | 11.51 M |
| EPS (ttm) | 1.91 |
| Forward PE | 11.58 |
| Ex-Dividend Date | 06/26/2025 |
| Earnings Date | 06/03/2025 |
PharmaSGP Holding SE's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/08/2025 | €320.05 M | 6.77% |
| 12/30/2024 | €299.76 M | 11.02% |
| 12/29/2023 | €270 M | -15.41% |
| 12/30/2022 | €319.2 M | 7.69% |
| 12/30/2021 | €296.4 M | -5% |
| 12/30/2020 | €312 M |
Company Profile
Company Overview
PharmaSGP Holding SE specializes in the manufacturing and sale of over-the-counter drugs and healthcare products, primarily in Germany. Founded in 2012 and headquartered in Gräfelfing, the company serves both domestic and international markets.
Key Products
- Baldriparan: A treatment for sleep disorders.
- Spalt, Formigran, Kamol: Massage creams for pain relief.
- RubaXX: Pharmaceutical drops for rheumatic pain.
- Restaxil: Drops for nerve pain in the neck and back.
- Revitensin: A drug for hair loss treatment.
- Dorisol: Addresses neuralgia, headaches, and migraines.
- Fulminan: A beauty drink.
- Lindaven: Drops for specific health concerns.
- SCLEROCALMAN: Treats clogged cerebral blood vessels.
- Prostacalman: Medication for cystitis and prostate-related discomfort.
- Revoten: Supports women with weak connective tissue.
- Mindalin: Micronutrient drink for cardiovascular health.
- MELISTON: Non-prescription tablets for anxiety and mood swings.
- Deruba: Cream for skin redness.
- Lentisol: Prevents new pigment spots.
- Neodolor: Headache relief tablets.
- DESEO: Drops for sexual weakness.
- Neradin: Addresses sexual dysfunction.
- TAUMEA: Treatment for vertigo.
Distribution & Market Reach
The company distributes its products through pharmacies and wholesalers. In addition to Germany, PharmaSGP exports to several European countries, including Austria, Italy, Belgium, Spain, and France.
Frequently Asked Questions
-
What is PharmaSGP Holding SE's (ETR-PSG) current market cap?As of 06/08/2025, PharmaSGP Holding SE (including the parent company, if applicable) has an estimated market capitalization of $364.65 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does PharmaSGP Holding SE (ETR-PSG) rank globally by market cap?PharmaSGP Holding SE global market capitalization ranking is approximately 16001 as of 06/08/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.